Last reviewed · How we verify
Kybella
At a glance
| Generic name | Kybella |
|---|---|
| Also known as | deoxycholic acid, ATX-101, Deoxycholate, Deoxycholic acid |
| Sponsor | Massachusetts General Hospital |
| Target | G-protein coupled bile acid receptor 1, fMet-Leu-Phe receptor, Bile acid receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Excess subcutaneous fat
Common side effects
- Injection site edema/swelling
- Injection site hematoma/bruising
- Injection site pain
- Injection site numbness
- Injection site erythema
- Injection site induration
- Injection site paresthesia
- Injection site nodule
- Injection site pruritus
- Headache
- Injection site skin tightness
- Injection site warmth
Serious adverse events
- Injection site ulceration
- Injection site necrosis
- Injection site infection
- Vascular injury due to inadvertent intravascular injection
- Hypersensitivity reactions (rash, urticaria, itching)
- Injection site scarring
- Oral hypoaesthesia
- Oral paraesthesia
- Pre-syncope/syncope
- Lymphadenopathy
Key clinical trials
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia (PHASE4)
- The Role of Secondary Bile Acids in Intestinal Inflammation (PHASE2, PHASE3)
- A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation (PHASE1)
- Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis (PHASE2)
- Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat (NA)
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kybella CI brief — competitive landscape report
- Kybella updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI